FAU in Treating Patients With Advanced Solid Tumors or Lymphoma

Inclusion Criteria

• •Measurable disease by CT scan and/or MRI
• •Archival tumor tissue sample available for correlative pharmacodynamic and pharmacogenomic studies
• •Accessible tumor tissue available (for patients enrolled in the expanded maximum tolerated dose \[MTD\] cohort)
• •No known active brain metastases but previously treated brain metastases allowed
• •ECOG performance status (PS) 0-1 OR Karnofsky PS 70-100%
• •AST and ALT =\< 2.5 times upper limit of normal (ULN) (=\< 5 times ULN if liver metastases are present)
• •Alkaline phosphatase =\< 2.0 times ULN (=\< 5 times ULN if bone or liver metastases are present)
• •Bilirubin normal
• •Creatinine normal or creatinine clearance \>= 60 mL/min
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •Willing to undergo tumor biopsies for correlative pharmacodynamic studies (for patients enrolled in the expanded MTD cohort)
• •Able to lie still for PET scan
• •Weight =\< 300 lbs
• •No uncontrolled illness including, but not limited to, any of the following:
• •* Ongoing or active infection
• •* Symptomatic congestive heart failure
• •* Unstable angina pectoris
• •* Cardiac arrhythmia
• •* Psychiatric illness/social situation that would preclude compliance with study requirements
• •No history of allergic reactions attributed to compounds of similar chemical or biologic composition to FAU
• •More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas, mitomycin C, or bleomycin), immunotherapy, or experimental therapy and recovered
• •More than 4 weeks since prior radiotherapy to \> 5% of total marrow volume
• •No prior radiotherapy to \>= 50% of total marrow volume
• •More than 3 weeks since prior radiotherapy to =\< 5% of total marrow volume
• •No other concurrent investigational agents
• •ANC \>= 1,500/mm\^3
• •Platelet count \>= 100,000/mm\^3
• •Life expectancy \> 12 weeks
• •Histologically or cytologically confirmed malignant solid tumor for which standard curative or palliative measures do not exist or are no longer effective
• •Solid hematologic malignancies (e.g., Hodgkin or non-Hodgkin lymphoma) allowed provided bone marrow biopsy has been performed within the past 6 weeks
• •Metastatic or unresectable disease
• •No other concurrent anticancer therapy (e.g., cytotoxic therapy, biologic therapy, radiotherapy, or hormonal therapy)
• •Concurrent hormone replacement therapy allowed
• •Concurrent megestrol acetate or bisphosphonates allowed provided they were started 1 month prior to study enrollment
• •Concurrent luteinizing hormone-releasing hormone agonists to maintain castrate levels of testosterone allowed for patients with prostate cancer